HOME >> BIOLOGY >> NEWS
Fat horses face health problems

but less than 8 and 19 percent of the horses were found to have a BCS of 8 to 9. Ten percent of the horses that had a BCS greater than 6 but less than 8 and 32 percent of the horses that had a BCS of 8 to 9 were hyperinsulinemic. These findings support the researchers hypothesis that the rate of overweight and obese horses is greater than the five percent figure reported in the 1998 NAHMS study.

The study suggests that equine obesity may result from natural grazing behavior instead of the overfeeding of grains and other feed supplements, which defies conventional thinking on equine weight matters. The majority of horses examined in the study were fed primarily pasture and hay with very little grain and concentrate.

Instead of overfeeding of grain and concentrates, the evidence indicates that improved forage and lack of exercise are the two most common contributing factors in equine obesity. Thatcher believes this may result from the fact that many pasture forages have been fortified with the goal of improving weight gain and productivity of cattle and other food animals, with little thought given to how these forages might affect horses, which often share the same types of pastures. In addition, the majority of the horses studied were under-exercised. They were left on pastures to eat, but did not have an actual exercise regimen.

Horses today are managed much differently from their evolutionary roots, indicated Dr. Pleasant. The horse evolved as a free-roaming grazer on sparse pasture types, he said. Later the horse served primarily as a work animal, serving as a source of transportation and draft power. Today, most horses serve as companions and light performance animals, he said.

We can see with increased nutrition and lack of exercise how these animals could drift toward being overweight, he said.

This research project remains underway, and has laid the groundwork for a series of provocative new studies. T
'"/>

Contact: Christy Jackson
cljacks@vt.edu
540-231-7239
Virginia Tech
9-Jul-2007


Page: 1 2 3 4 5

Related biology news :

1. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
2. Vets seeing more horses with nutritional issues this year
3. Witonsky honored with Pfizer award for work with EPM disease in horses
4. Basque Country horses
5. Virginia Tech researcher examining malignant melanoma in horses
6. Study shows how respiratory disorder slows some racehorses
7. Racehorses, asthmatics, meatpackers may have similar etiology of airway disturbances
8. UF researcher: Ideas about fossil horses undergo evolution in thinking
9. Particle emissions from laser printers might pose health concern
10. Cell damage caused by brushing may help keep gums healthy
11. New studies on goats milk show it is more beneficial to health than cows milk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fat horses face health problems

(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: